LFCR

Business Context and Reporting Period

Lifecore Biomedical, Inc. (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products and hyaluronic acid (HA) manufacturing. This Form 10-Q covers the quarterly period ended June 30, 2026. The Company recently transitioned from a fiscal year ending the last Sunday of May to a calendar year ending December 31, effective August 1, 2025. Consequently, comparative data is presented for the three and six months ended May 25, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 6% ($2.3M) for the quarter and 20% ($14.2M) for the six months compared to the prior period. This was driven primarily by a significant drop in CDMO revenue due to lower sales volumes and the completion of discrete development projects in the prior year. HA manufacturing revenue increased 44% in the quarter but declined 5% for the six months.
• Margin Compression: Gross profit margins declined to 35.3% (Q2) and 28.8% (YTD) from 38.4% and 33.3% respectively in the prior year, attributed to unfavorable net realizable value adjustments and manufacturing variances in the CDMO segment.
• Expense Reductions: Operating expenses decreased significantly. SG&A expenses fell 11% ($1.0M) for the quarter and 17% ($3.2M) for the six months, driven by lower legal/accounting fees and reduced non-recurring costs. R&D expenses also declined due to headcount reductions and increased utilization of personnel on revenue-generating projects.
• Interest Expense Surge: Net interest expense increased 38% ($2.1M) for the quarter and 35% ($3.8M) for the six months. This is primarily due to the accumulation of interest paid-in-kind (PIK) on the related-party term loan with Alcon and the amortization of debt discounts.
• Debt Derivative Liability: The change in fair value of the debt derivative liability resulted in a non-operating loss of $1.2M for the quarter and $4.4M for the six months, an increase from the prior year due to changes in valuation inputs and discount rates.

Outlook, Risks, and Contingencies

• Preferred Stock Redemption: Holders of Series A Redeemable Convertible Preferred Stock have exercised their right to redeem all 49,263 shares. The redemption date is December 28, 2026, with a total obligation of approximately $50.2 million (including accrued dividends). The Company currently lacks sufficient cash to fund this redemption and must obtain lender waivers or pursue strategic alternatives (equity/debt financing) to avoid a breach of credit agreements.
• Liquidity Position: As of June 30, 2026, the Company had $17.2 million in cash and $21.6 million available under its Revolving Credit Facility. It remains in compliance with its minimum liquidity covenant of $4.0 million.
• Legal Proceedings:
  • Class Action: A proposed settlement regarding a securities class action was preliminarily approved by the court in March 2026, with final approval pending. The Company expects this to be covered by insurance with no material loss.
  • Investor Dispute: A lawsuit by 22NW Fund regarding registration delay fees and misrepresentations is ongoing. Most claims were dismissed, but the Company intends to defend against remaining claims regarding express representations.
  • Yucatan Litigation: Ongoing litigation regarding the 2018 acquisition of Yucatan Foods involves multiple defendants and appeals. The outcome remains uncertain.
• Internal Controls: The Company disclosed a material weakness in internal controls over financial reporting related to its legacy ERP system. While a new ERP system was launched in January 2026, the weakness has not yet been fully remediated as of June 30, 2026.

Investor Verification Checklist

• Preferred Stock Redemption Plan: Verify the Company's specific strategy and timeline for raising the ~$50 million required to redeem the Series A Preferred Stock by December 2026.
• Alcon Dependency: Confirm the stability of the relationship with Alcon, which represents 55% of revenue and is the primary lender (related party debt of ~$193M).
• Interest Rate Impact: Assess the long-term impact of the 20.9% effective interest rate on the term loan and the compounding effect of interest paid-in-kind on future debt principal.
• ERP Remediation: Monitor the progress of the new ERP system implementation and the timeline for closing the material weakness in internal controls.
• CDMO Pipeline: Evaluate the pipeline of new development projects to offset the decline in CDMO revenue caused by the completion of prior projects.